by Virtus | Apr 11, 2026 | Early-Stage Respiratory Drug Development
Outsourcing vs in-house respiratory research is a common consideration for biotech and pharmaceutical companies developing therapies for asthma, COPD, and viral respiratory diseases. Respiratory drug development requires specialised preclinical models, in vivo...
by Virtus | Apr 11, 2026 | Early-Stage Respiratory Drug Development
Finding the best respiratory CRO in the UK is a key step for biotech and pharmaceutical companies developing therapies for asthma, COPD, and viral respiratory diseases. Respiratory drug development requires specialised preclinical models, in vivo respiratory studies,...
by Virtus | Mar 21, 2026 | Early-Stage Respiratory Drug Development
Selecting a respiratory preclinical CRO in the UK is a key decision in early stage respiratory drug development. Respiratory diseases such as asthma, COPD, and viral respiratory infections require disease-specific preclinical models, in vivo respiratory studies, and...
by Virtus | Mar 21, 2026 | Early-Stage Respiratory Drug Development
Preclinical feasibility studies respiratory programmes are used in early stage respiratory drug development to evaluate whether a therapeutic candidate demonstrates sufficient biological activity to justify further progression. These studies are typically designed to...
by Virtus | Mar 21, 2026 | Early-Stage Respiratory Drug Development
Outsourcing respiratory research in the UK is a common strategy for biotech and pharmaceutical companies seeking specialist expertise in preclinical respiratory studies. Respiratory drug development often requires disease-specific models, in vivo respiratory studies,...
by Virtus | Feb 4, 2026 | Early-Stage Respiratory Drug Development
Early stage respiratory drug development focuses on evaluating therapeutic feasibility, biological activity, and translational relevance before compounds progress into clinical investigation. At this stage, preclinical respiratory studies are designed to generate...
